Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour

Psychopharmacology

Volumn 219, Issue 3, 2012, Pages 859-873

  Deiana, Serena ^a   Watanabe, Akihito ^a,b   Yamasaki, Yuki ^a,b   Amada, Naoki ^a,b   Arthur, Marlene ^a   Fleming, Shona ^a   Woodcock, Hilary ^a   Dorward, Patricia ^a   Pigliacampo, Barbara ^a   Close, Steve ^a   Platt, Bettina ^a   Riedel, Gernot ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Area under curve; Bioavailability; Elimination half life; Mice; Pharmacodynamic; Pharmacokinetic; Phytocannabinoids; Rats; Systemic administration

Indexed keywords

CANNABIDIOL; CANNABIGEROL; CANNABINOID; CANNABIVARINE; DELTA 9 TETRAHYDROCANNABIVARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CANNABIDIOL; CANNABINOIDS; COMPULSIVE BEHAVIOR; INJECTIONS, INTRAPERITONEAL; MALE; MICE; OBSESSIVE BEHAVIOR; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL;

EID: 84856628201     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2415-0     Document Type: Article

References (76)

1. EL Abel DE McMillan LS Harris 1974 D9-Tetrahydro-cannabinol: effects of routes of administration on onset and duration of activity and tolerance development Psychopharmacologia 35 29 10.1007/BF00421563 1:CAS:528: DyaE2cXksVGhs70%3D
2. A Aghazadeh-Habashi A Ibrahim J Carran T Anastassiades F Jamali 2006 Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat J Pharm Pharm Sci 9 359 364 17207418 1:CAS:528:DC%2BD28XhtlCmsbjM (Pubitemid 46629865)
3. S Agurell M Halldin JE Lindgren A Ohlsson M Widman H Gillespie L Hollister 1986 Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man Pharmacol Rev 38 21 43 3012605 1:CAS:528:DyaL28XktlCqs70%3D (Pubitemid 16077324)
4. SO Alozie BR Martin LS Harris WL Dewey 1980 3H-delta 9- Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain Pharmacol Biochem Behav 12 217 221 6246544 10.1016/0091-3057(80)90359-7 1:CAS:528:DyaL3cXks1Sru74%3D (Pubitemid 10110132)
5. G Appendino S Gibbons A Giana A Pagani G Grassi M Stavri E Smith MM Rahman 2008 Antibacterial cannabinoids from Cannabis sativa: a structure-activity study J Nat Prod 71 1427 1430 10.1021/np8002673 18681481 10.1021/np8002673 1:CAS:528:DC%2BD1cXptl2ht7Y%3D
6. SH Baek YO Kim JS Kwag KE Choi WY Jung DS Han 1998 Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells Arch Pharm Res 21 353 356 9875457 10.1007/BF02975301 1:CAS:528:DyaK1cXjvFWit7o%3D (Pubitemid 128661023)
7. FR Bambico A Duranti A Tontini G Tarzia G Gobbi 2009 Endocannabinoids in the treatment of mood disorders: evidence from animal models Curr Pharm Des 15 1623 1646 19442178 10.2174/138161209788168029 1:CAS:528:DC%2BD1MXmtValt70%3D
8. I Barna I Till J Haller 2009 Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain Eur Neuropsychopharmacol 19 533 541 10.1016/j.euroneuro.2009.02.001 19303746 10.1016/j.euroneuro.2009.02.001 1:CAS:528:DC%2BD1MXnvVWntbY%3D
9. M Bifulco C Grimaldi P Gazzerro S Pisanti A Santoro 2007 Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects Mol Pharmacol 71 1445 1456 10.1124/mol.106.033118 17327463 10.1124/mol.106.033118 1:CAS:528:DC%2BD2sXmt1Wqt7w%3D (Pubitemid 47010897)
10. T Bisogno L Hanus L De Petrocellis S Tchilibon DE Ponde I Brandi AS Moriello JB Davis R Mechoulam V Di Marzo 2001 Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br J Pharmacol 134 845 852 10.1038/sj.bjp.0704327 11606325 10.1038/sj.bjp.0704327 1:CAS:528: DC%2BD3MXotlChsbk%3D (Pubitemid 33016156)
11. B Bittner RC Gonzalez I Walter M Kapps J Huwyler 2003 Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats Biopharm Drug Dispos 24 173 181 10.1002/bdd.353 12698501 10.1002/bdd.353 1:CAS:528:DC%2BD3sXkt1Ohu7Y%3D (Pubitemid 36656391)
12. D Bolognini B Costa S Maione F Comelli P Marini V Di Marzo D Parolaro RA Ross LA Gauson MG Cascio RG Pertwee 2010 The plant cannabinoid delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice Br J Pharmacol 160 677 687 10.1111/j.1476-5381.2010. 00756.x 20590571 10.1111/j.1476-5381.2010.00756.x 1:CAS:528:DC%2BC3cXpslyqsr8%3D
13. F Borsini J Podhorna D Marazziti 2002 Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163 121 141 10.1007/s00213-002-1155-6 10.1007/s00213-002-1155-6 1:CAS:528: DC%2BD38XosVGrt70%3D (Pubitemid 35013604)
14. CL Broekkamp HW Rijk D Joly-Gelouin KL Lloyd 1986 Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice Eur J Pharmacol 126 223 229 2875886 10.1016/0014-2999(86)90051-8 1:CAS:528:DyaL28Xlt1Kks7w%3D (Pubitemid 16016552)
15. M Carey TG Burish DE Brenner 1983 delta-9-Tetrahydrocannabinol in cancer chemotherapy: research problems and issues Ann Intern Med 99 106 6305249 1:STN:280:DyaL3s3ivFamug%3D%3D
16. EA Carlini 2004 The good and the bad effects of (-) trans-delta-9- tetrahydrocannabinol (delta 9-THC) on humans Toxicon 44 461 467 10.1016/j.toxicon.2004.05.009 15302527 10.1016/j.toxicon.2004.05.009 1:CAS:528:DC%2BD2cXmtlOksLo%3D (Pubitemid 39070645)
17. PC Casarotto FV Gomes LB Resstel FS Guimaraes 2010 Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors Behav Pharmacol 21 353 358 20695034 10.1097/FBP.0b013e32833b33c5 1:CAS:528: DC%2BC3cXptVyrtLs%3D
18. MG Cascio LA Gauson LA Stevenson RA Ross RG Pertwee 2010 Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist Br J Pharmacol 159 129 141 10.1111/j.1476-5381.2009.00515.x 20002104 10.1111/j.1476-5381.2009.00515.x 1:CAS:528:DC%2BC3cXhtFynt70%3D
19. Claassen V (1994) Neglected factors in pharmacology and neuroscience research. Elsevier, Amsterdam
20. BK Colasanti 1990 A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol J Ocul Pharmacol 6 259 269 1965836 10.1089/jop.1990.6.259 1:CAS:528:DyaK3MXit1Wgsbg%3D
21. BK Colasanti CR Craig RD Allara 1984 Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol Exp Eye Res 39 251 259 6499952 10.1016/0014-4835(84)90013-7 1:CAS:528: DyaL2MXjvFyktw%3D%3D (Pubitemid 15158975)
22. G Cornaire J Woodley P Hermann A Cloarec C Arellano G Houin 2004 Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int J Pharm 278 119 131 10.1016/j.ijpharm.2004.03.001 15158955 10.1016/j.ijpharm.2004.03.001 1:CAS:528:DC%2BD2cXktFOiur4%3D (Pubitemid 38670443)
23. L De Leo N Di Toro G Decorti N Malusa A Ventura T Not 2010 Fasting increases tobramycin oral absorption in mice Antimicrob Agents Chemother 54 1644 1646 10.1128/AAC.01172-09 20086144 10.1128/AAC.01172-09
24. B de Mattos Viana HA Prais MV Daker 2009 Melancholic features related to rimonabant Gen Hosp Psychiatry 31 583 585 10.1016/j.genhosppsych.2008.12.009 19892218 10.1016/j.genhosppsych.2008.12.009
25. JP Despres 2009 Pleiotropic effects of rimonabant: clinical implications Curr Pharm Des 15 553 570 19199981 10.2174/138161209787315666 1:CAS:528:DC%2BD1MXkvVSntL8%3D
26. MA Elsohly D Slade 2005 Chemical constituents of marijuana: the complex mixture of natural cannabinoids Life Sci 78 539 548 10.1016/j.lfs.2005.09.011 16199061 10.1016/j.lfs.2005.09.011 1:CAS:528:DC%2BD2MXht1ejsrfJ (Pubitemid 41653504)
27. JY Fang SH Hsu YL Leu JW Hu 2009 Delivery of cisplatin from pluronic co-polymer systems: liposome inclusion and alginate coupling J Biomater Sci Polym Ed 20 1031 1047 10.1163/156856209X444493 19454167 10.1163/156856209X444493 1:CAS:528:DC%2BD1MXmvFKrsbg%3D
28. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647
29. EW Gill WD Paton RG Pertwee 1970 Preliminary experiments on the chemistry and pharmacology of cannabis Nature 228 134 136 5466704 10.1038/228134a0 1:CAS:528:DyaE3MXisFKk
30. FV Gomes PC Casarotto LB Resstel FS Guimaraes 2011 Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice Prog Neuropsychopharmacol Biol Psychiatry 35 434 438 10.1016/j.pnpbp.2010.11.027 21111767 10.1016/j.pnpbp.2010.11.027 1:CAS:528:DC%2BC3MXjvVaqtro%3D
31. JP Goulle E Saussereau C Lacroix 2008 delta-9-Tetrahydrocannabinol pharmacokinetics Ann Pharm Fr 66 232 244 10.1016/j.pharma.2008.07.006 18847571 10.1016/j.pharma.2008.07.006 1:CAS:528:DC%2BD1cXht1yjtLvK
32. M Guzman C Sanchez I Galve-Roperh 2002 Cannabinoids and cell fate Pharmacol Ther 95 175 184 12182964 10.1016/S0163-7258(02)00256-5 1:CAS:528:DC%2BD38XmtlKjsrw%3D (Pubitemid 35232135)
33. AJ Hill SE Weston NA Jones I Smith SA Bevan EM Williamson GJ Stephens CM Williams BJ Whalley 2010 delta-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats Epilepsia 51 1522 1532 10.1111/j.1528-1167.2010.02523.x 20196794 10.1111/j.1528-1167.2010.02523.x 1:CAS:528:DC%2BC3cXhtFKktrnM
34. KW Hillig PG Mahlberg 2004 A chemotaxonomic analysis of cannabinoids variation in Cannabis (Cannabaceae) Am J Bot 91 966 21653452 10.3732/ajb.91.6.966 1:CAS:528:DC%2BD2cXpvFajtr4%3D
35. BT Ho GE Fritchie LF Englert WM McIsaac JE Idanpaan-Heikkila 1971 Marihuana: importance of the route of administration J Pharm Pharmacol 23 309 310 4396913 10.1111/j.2042-7158.1971.tb08666.x 1:CAS:528:DyaE3MXhtl2htr4%3D
36. LE Hollister 1974 Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol Pharmacology 11 3 11 4610598 10.1159/000136462 1:CAS:528:DyaE2cXksVGju7o%3D
37. T Iuvone G Esposito D De Filippis C Scuderi L Steardo 2009 Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15 65 75 10.1111/j.1755-5949.2008.00065.x 19228180 10.1111/j.1755-5949.2008.00065.x 1:CAS:528:DC%2BD1MXjvFOnsb0%3D
38. Iversen L (2007) The science of marijuana. Oxford University Press, Oxford
39. AB Jones MA Elsohly JA Bedford CE Turner 1981 Determination of cannabidiol in plasma by electron-capture gas chromatography J Chromatogr 226 99 105 7320159 10.1016/S0378-4347(00)84210-3 1:CAS:528:DyaL38XhsFY%3D (Pubitemid 12223704)
40. A Kast J Nishikawa 1981 The effect of fasting on oral acute toxicity of drugs in rats and mice Lab Anim 15 359 364 6122759 10.1258/002367781780952933 1:CAS:528:DyaL38Xmt1KisA%3D%3D (Pubitemid 12209977)
41. FM Leweke D Koethe F Pahlisch D Schreiber CW Gerth BM Nolden J Klosterkötter M Hellmich D Piomelli 2009 Antipsychotic effects of cannabidiol. 17th EPA Congress Eur Psychiatry 24 S207 10.1016/S0924-9338(09) 70440-7
42. X Li D Morrow JM Witkin 2006 Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying Life Sci 78 1933 1939 10.1016/j.lfs.2005.08.002 16182315 10.1016/j.lfs.2005.08.002 1:CAS:528:DC%2BD28XitVGgsrc%3D
43. A Ligresti AS Moriello K Starowicz I Matias S Pisanti L De Petrocellis C Laezza G Portella M Bifulco V Di Marzo 2006 Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma J Pharmacol Exp Ther 318 1375 1387 10.1124/jpet.106.105247 16728591 10.1124/jpet.106.105247 1:CAS:528:DC%2BD28XovFygtLY%3D (Pubitemid 44268348)
44. B Mantilla-Plata RD Harbison 1975 Distribution studies of (14C)delta-9-tetrahydrocannabinol in mice: effect of vehicle, route of administration, and duration of treatment Toxicol Appl Pharmacol 34 292 300 1209626 10.1016/0041-008X(75)90034-4 1:CAS:528:DyaE28XmvFahtQ%3D%3D
45. LB Nicolas Y Kolb EP Prinssen 2006 A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants Eur J Pharmacol 547 106 115 10.1016/j.ejphar.2006.07.015 16934246 10.1016/j.ejphar.2006.07.015 1:CAS:528:DC%2BD28Xps1OmtLo%3D (Pubitemid 44373902)
46. K Njung'e SL Handley 1991 Evaluation of marble-burying behavior as a model of anxiety Pharmacol Biochem Behav 38 63 67 2017455 10.1016/0091-3057(91) 90590-X
47. T Perrier P Saulnier F Fouchet N Lautram JP Benoit 2010 Post-insertion into lipid nanocapsules (LNCs): from experimental aspects to mechanisms Int J Pharm 396 204 209 10.1016/j.ijpharm.2010.06.019 20600733 10.1016/j.ijpharm.2010. 06.019 1:CAS:528:DC%2BC3cXpt1SqtLo%3D
48. RG Pertwee AC Howlett ME Abood SP Alexander V Di Marzo MR Elphick PJ Greasley HS Hansen G Kunos K Mackie R Mechoulam RA Ross 2010 International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 Pharmacol Rev 62 588 631 10.1124/pr.110.003004 21079038 10.1124/pr.110.003004 1:CAS:528:DC%2BC3MXktler
49. RG Pertwee 2008 The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Br J Pharmacol 153 199 215 10.1038/sj.bjp.0707442 17828291 10.1038/sj.bjp.0707442 1:CAS:528:DC%2BD1cXovFCkuw%3D%3D
50. RG Pertwee 2007 GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152 984 986 10.1038/sj.bjp.0707464 17876300 10.1038/sj.bjp.0707464 1:CAS:528:DC%2BD2sXhtlCrsbnJ (Pubitemid 350166047)
51. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic/Plenum, New York, p 32
52. RG Pertwee 1997 Pharmacology of cannabinoid CB1 and CB2 receptors Pharmacol Ther 74 129 180 9336020 10.1016/S0163-7258(97)82001-3 1:CAS:528:DyaK2sXkvFChsL0%3D (Pubitemid 27337346)
53. SR Plotkin WA Banks LM Maness AJ Kastin 2000 Differential transport of rat and human interleukin-1alpha across the blood-brain barrier and blood-testis barrier in rats Brain Res 881 57 61 11033093 10.1016/S0006-8993(00)02772-4 1:CAS:528:DC%2BD3cXntF2gsLY%3D
54. G Riedel P Fadda S McKillop-Smith RG Pertwee B Platt L Robinson 2009 Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice Br J Pharmacol 156 1154 1166 19378378 10.1111/j.1476-5381.2008.00107.x 1:CAS:528:DC%2BD1MXltFSmu7g%3D
55. DJ Rog 2010 Cannabis-based medicines in multiple sclerosis-a review of clinical studies Immunobiology 215 658 672 10.1016/j.imbio.2010.03.009 20541836 10.1016/j.imbio.2010.03.009 1:CAS:528:DC%2BC3cXpsVCks7c%3D
56. EB Russo A Burnett B Hall KK Parker 2005 Agonistic properties of cannabidiol at 5-HT1a receptors Neurochem Res 30 1037 1043 10.1007/s11064-005- 6978-1 16258853 10.1007/s11064-005-6978-1 1:CAS:528:DC%2BD2MXhtFKmsbrE (Pubitemid 41570039)
57. E Ryberg N Larsson S Sjogren S Hjorth NO Hermansson J Leonova T Elebring K Nilsson T Drmota PJ Greasley 2007 The orphan receptor GPR55 is a novel cannabinoid receptor Br J Pharmacol 152 1092 1101 10.1038/sj.bjp.0707460 17876302 10.1038/sj.bjp.0707460 1:CAS:528:DC%2BD2sXhtlCrsbnI (Pubitemid 350166046)
58. E Samara M Bialer R Mechoulam 1988 Pharmacokinetics of cannabidiol in dogs Drug Metab Dispos 16 469 472 2900742 1:CAS:528:DyaL1cXksVOkurg%3D
59. A Scutt EM Williamson 2007 Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors Calcif Tissue Int 80 50 59 10.1007/s00223-006-0171-7 17205329 10.1007/s00223-006-0171-7 1:CAS:528:DC%2BD2sXktFCltg%3D%3D (Pubitemid 46098877)
60. BB Sethi JK Trivedi P Kumar A Gulati AK Agarwal N Sethi 1986 Antianxiety effect of cannabis: involvement of central benzodiazepine receptors Biol Psychiatry 21 3 10 3002503 10.1016/0006-3223(86)90003-X 1:CAS:528: DyaL28Xls1CqtLg%3D (Pubitemid 16043729)
61. AJ Siemens D Walczak FE Buckley 1980 Characterization of blood disappearance and tissue distribution of [3H]cannabidiol Biochem Pharmacol 29 462 464 7362660 10.1016/0006-2952(80)90532-8 1:CAS:528:DyaL3cXhvFWjs7o%3D (Pubitemid 10199557)
62. DA Smith L Di EH Kerns 2010 The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat Rev Drug Discov 9 929 939 10.1038/nrd3287 21119731 10.1038/nrd3287 1:CAS:528:DC%2BC3cXhsV2jurfI
63. AH Soderpalm A Schuster H de Wit 2001 Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac Pharmacol Biochem Behav 69 343 350 11509190 10.1016/S0091-3057(01)00533-0 1:CAS:528:DC%2BD3MXlvFWku78%3D (Pubitemid 32758716)
64. S Syvanen O Lindhe M Palner BR Kornum O Rahman B Langstrom GM Knudsen M Hammarlund-Udenaes 2009 Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab Dispos 37 635 643 10.1124/dmd.108.024745 19047468 10.1124/dmd.108.024745
65. H Takeuchi S Yatsugi T Yamaguchi 2002 Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model Jpn J Pharmacol 90 197 200 12419892 10.1254/jjp.90.197 1:CAS:528:DC%2BD38XotlCnur0%3D (Pubitemid 35291307)
66. A Thomas A Burant N Bui D Graham LA Yuva-Paylor R Paylor 2009 Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety Psychopharmacology (Berl) 204 361 373 10.1007/s00213-009-1466-y 10.1007/s00213-009-1466-y 1:CAS:528: DC%2BD1MXhtlyhsrk%3D
67. A Thomas GL Baillie AM Phillips RK Razdan RA Ross RG Pertwee 2007 Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro Br J Pharmacol 150 613 623 10.1038/sj.bjp.0707133 17245363 10.1038/sj.bjp.0707133 1:CAS:528:DC%2BD2sXisVeis7Y%3D (Pubitemid 46355558)
68. A Thomas LA Stevenson KN Wease MR Price G Baillie RA Ross RG Pertwee 2005 Evidence that the plant cannabinoid delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist Br J Pharmacol 146 917 926 10.1038/sj.bjp.0706414 16205722 10.1038/sj.bjp.0706414 1:CAS:528: DC%2BD2MXht1Ghu7jE (Pubitemid 41722163)
69. A Tubaro A Giangaspero S Sosa R Negri G Grassi S Casano R Della Loggia G Appendino 2010 Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins Fitoterapia 81 816 819 10.1016/j.fitote.2010.04.009 20450962 10.1016/j.fitote.2010.04.009 1:CAS:528:DC%2BC3cXhtFCrtLbM
70. D Turcotte JA Le Dorze F Esfahani E Frost A Gomori M Namaka 2010 Examining the roles of cannabinoids in pain and other therapeutic indications: a review Expert Opin Pharmacother 11 17 31 10.1517/14656560903413534 20001426 10.1517/14656560903413534 1:CAS:528:DC%2BD1MXhsFCitLvP
71. S Valiveti DC Hammell DC Earles AL Stinchcomb 2004 Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro/in vivo correlation Pharm Res 21 1137 1145 15290852 10.1023/B:PHAM.0000032999.31948.2e 1:CAS:528:DC%2BD2cXltF2gtrY%3D (Pubitemid 38954197)
72. EA Voth RH Schwartz 1997 Medicinal applications of delta-9- tetrahydrocannabinol and marijuana Ann Intern Med 126 791 798 9148653 1:CAS:528:DyaK2sXjs1emu7k%3D (Pubitemid 27209646)
73. LS Whyte E Ryberg NA Sims SA Ridge K Mackie PJ Greasley RA Ross MJ Rogers 2009 The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo Proc Natl Acad Sci USA 106 16511 16516 10.1073/pnas.0902743106 19805329 10.1073/pnas.0902743106 1:CAS:528: DC%2BD1MXht1Kqtb7E
74. K Woodburn E Sykes D Kessel 1995 Interactions of Solutol HS 15 and cremophor EL with plasma lipoproteins Int J Biochem Cell Biol 27 693 699 7648425 10.1016/1357-2725(95)00030-S 1:CAS:528:DyaK2MXns1eitLk%3D
75. AW Zuardi 2008 Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action Rev Bras Psiquiatr 30 271 280 18833429 10.1590/S1516-44462008000300015
76. AW Zuardi JA Crippa JE Hallak FA Moreira FS Guimaraes 2006 Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Braz J Med Biol Res 39 421 429 16612464 10.1590/S0100-879X2006000400001 1:CAS:528:DC%2BD28XkvFGjtbk%3D